Skip to main content
Christian Tvetenstrand, MD, General Surgery, Johnson City, NY

ChristianTvetenstrandMD

General Surgery Johnson City, NY

Bariatric Surgery, Colon & Rectal Surgery, Trauma Surgery & Surgical Critical Care

Physician

Dr. Tvetenstrand is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Tvetenstrand's full profile

Already have an account?

  • Office

    30 Harrison St
    Suite 320
    Johnson City, NY 13790
    Phone+1 607-763-8205
    Fax+1 607-763-8208

Education & Training

  • New York Medical College at St Vincent's Hospital and Medical Center of New York
    New York Medical College at St Vincent's Hospital and Medical Center of New YorkResidency, Surgery, 1983 - 1989
  • Rutgers New Jersey Medical School
    Rutgers New Jersey Medical SchoolClass of 1983

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1989 - 2025
  • American Board of Surgery Surgery

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification MEDENT EMR/EHR, Community Computer Service, Inc., 2011-2012

Publications & Presentations

PubMed

Press Mentions

  • AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery
    AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement SurgeryJanuary 12th, 2022
  • AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery
    AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement SurgeryDecember 15th, 2021
  • AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery
    AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement SurgeryDecember 15th, 2021
  • Join now to see all